Dr. RASHMI KUMARI

Dr. BIBHUTI PRASSAN SINHA, Dr. BHAWESH SAHA, Dr. VIDYA BHUSHAN KUMAR

Abstract

To evaluate the effects of topical ROCK inhibitor, Ripatec 0.4%.in refractory glaucoma patients as add on therapy,a prospective interventional study at a tertiary eye centre was conducted between Dec19-March 20. 25 eyes of 25 patients of refractory glaucoma with uncontrolled IOP despite maximam glaucoma medication were included in the study .Topical Ripatec 0.4% BD was added to the existing medical regimen. Follow up was done at 1, 2, 3, 4, and 8 weeks and IOP and adverse reactions were evaluated. Baseline mean IOP was 31.5 +/- 3.4 mm Hg and mean IOP reductions of the last visit was -8.25 +/- 1.2 mm Hg which was statistically significant . Conjunctival hyperemia and blepharitis were found in 5 patients (20%) and 3 patients (12%) respectively.Hyperemia lasted for 4 hours only.Conclusion : Topical Ripasudil in refractory glaucoma causes significant reduction in IOP (20%) and is well tolerated. ROCK inhibitors could be given a trial before switching over to incisional surgeries .

Full Text